ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
P. Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Y. Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz M. Kowalski, Jerónimo Rafael Rodríguez‐Cid, Praveen Aanur, Christine Baudelet, Gérard Zalcman
Topics & Concepts
MedicineNivolumabPemetrexedIpilimumabOncologyInternal medicineChemotherapyMesotheliomaCancerImmunotherapyPathologyCisplatinOccupational and environmental lung diseasesCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research